Back to Search
Start Over
Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
- Source :
- Medical oncology (Northwood, London, England). 36(10)
- Publication Year :
- 2019
-
Abstract
- Nab-paclitaxel plus gemcitabine (Nab-Gem) represents one of the standard regimen for first-line treatment of metastatic pancreatic adenocarcinoma (mPDAC). However, few data are available in mPDAC relapsed after gemcitabine as adjuvant treatment. Our study aims to evaluate the efficacy and feasibility of Nab-Gem as first-line treatment for mPDAC patients previously treated with adjuvant treatment. We retrospectively analyzed the safety and efficacy data of 36 patients, who received first-line Nab-Gem after gemcitabine as adjuvant treatment. All patients received gemcitabine after radical surgery. Median disease-free survival was 12 months (95% CI 9.7-14.3); at relapse, all patients received Nab-Gem. We observed an objective response rate and disease control rate of 11.1% and 63.9%, respectively. With a median follow-up of 47 months, median progression-free survival was 5 months (95% CI 1.0-9.0), whereas median overall survival (OS) was 13 months (95% CI 5.5-20.5). Median OS was higher in patients with a relapse >= 7 months after the end of adjuvant treatment than in patients relapsed < 7 months (14 vs. 8 months, respectively, p: 0.52). Our results show that first-line Nab-Gem is feasible and effective in patients previously treated with gemcitabine as adjuvant treatment.
- Subjects :
- Oncology
Adult
Male
Cancer Research
medicine.medical_specialty
Paclitaxel
medicine.medical_treatment
Metastatic pancreatic adenocarcinoma
Adenocarcinoma
Deoxycytidine
Disease-Free Survival
03 medical and health sciences
0302 clinical medicine
Internal medicine
Pancreatic cancer
Albumins
Metastatic pancreatic cancer
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Radical surgery
Adjuvant
Aged
Retrospective Studies
Hematology
business.industry
General Medicine
Nab-paclitaxel and gemcitabine
Metastatic Pancreatic Adenocarcinoma
Middle Aged
medicine.disease
Gemcitabine
Pancreatic Neoplasms
Regimen
Treatment Outcome
Chemotherapy, Adjuvant
030220 oncology & carcinogenesis
Female
Neoplasm Recurrence, Local
business
medicine.drug
Subjects
Details
- ISSN :
- 1559131X
- Volume :
- 36
- Issue :
- 10
- Database :
- OpenAIRE
- Journal :
- Medical oncology (Northwood, London, England)
- Accession number :
- edsair.doi.dedup.....821f503a9071a86d1694eeba334d345e